Professor Jeremy Everett Faculty of Engineering & Science

Professor Jeremy Everett is Professor of Pharmaceutical Technologies in the Department of Pharmaceutical, Chemical & Environmental Sciences within the School of Science.

Professor Everett's main research focus is in metabolic profiling, also known as metabonomics or metabolomics. He has a particular interest in studying the consequences of genetic mutations on metabolic phenotypes and on the interplay between the genome and microbiome. He co-conceived, and named and defined metabonomics together with Professor Jeremy Nicholson (Imperial College, London), with whom he has a long-standing collaboration. He is a co-discoverer of pharmacometabonomics: which is the ability to predict the effects of drugs prior to dosing via metabolic profiling, and he is a co-inventor on a granted patent on pharmacometabonomics. He is a Visiting Professor in the Department of Surgery and Cancer at Imperial College. He is also currently the Acting Director of the Singapore Phenome Centre and is a scientific consultant and a Visiting Professor at the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore.

Professor Everett is a co-leader of the Medway Metabonomics Group (MMRG) together with Dr Ruey-Leng Loo from the School of Pharmacy.

Professor Everett is the author of nearly 100 publications and reviews and a co-inventor on 3 patents. He has an H-index of 28 and has been cited in the literature over 4,000 times, with his top 4 papers each cited over 400 times.

Professor Everett consults for both major pharmaceutical and small biotech and research institutes on drug discovery. He is also a consultant for a New York law firm on pharmaceutical patents.

Prior to his current position, Professor Everett held a variety of drug discovery technology leadership positions at Pfizer, and before that, SmithKline Beecham and Beecham Research Laboratories. These positions included responsibilities for analytical sciences, automated purification, biobanking, chemoinformatics, computational chemistry, ligand-based drug design, curation, management and provision of the compound screening file, data support and management, lead generation by high throughput screening, compound library design and production, indications discovery, structural biology, structure-based drug design and drug target analysis.

Professor Everett received both his BSc in chemistry and PhD in physical organic chemistry from Nottingham University. He was a Post-doctoral Fellow at McMaster University in Hamilton, Ontario, and a Research Associate at McGill University, Montréal.